CStone Pharma (基石药业) Post-IPO: Strong Debut but Lacks near Term Catalysts
CStone Pharma's IPO was priced at HKD 12.00/share and started trading today. In this insight, we summarize the allocation, the use of proceeds and...
548 Views
CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)
CStone Pharma, a Wuxi Apptec related biotech company, plans to raise USD 300m to list on the Hong Kong Stock Exchange. In our previous insight...
758 Views
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.1k Views
CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates
CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical...
649 Views
Last Week in GER IPO Research: Leong Hup, China Tobacco, Futu and Weimob
We slide into 2019 with GER's recap of our latest IPO research. This week, we talk chicken as Arun initiates on the IPO Malaysian poultry producer...
610 Views